The identification of key tumorigenic events in Sonic Hedgehog (SHH) subgroup medulloblastomas (MB SHH ) will be essential for the development of individualized therapies and improved outcomes. However, beyond confirmation of characteristic SHH pathway mutations, recent genome-wide sequencing studies have not revealed commonly mutated genes with widespread relevance as potential therapeutic targets. We therefore examined any role for epigenetic DNA methylation events in MB SHH using a crossspecies approach to candidate identification, prioritization and validation. MB SHH -associated DNA methylation events were first identified in 216 subgrouped human medulloblastomas (50 MB SHH , 28 Wnt/Wingless, 44 Group 3 and 94 Group 4) and their conservation then assessed in tumors arising from four independent murine models of Shh medulloblastoma, alongside any role in tumorigenesis using functional assessments in mouse and human models. This strategy identified widespread regional CpG hypomethylation of VAV1, leading to its elevated expression, as a conserved aberrant epigenetic event, which characterizes the majority of MB SHH tumors in both species, and is associated with a poor outcome in MB SHH patients. Moreover, direct modulation of VAV1 in mouse and human models revealed a critical role in tumor maintenance, and its abrogation markedly reduced medulloblastoma growth. Further, Vav1 activity regulated granule neuron precursor germinal zone exit and migration initiation in an ex vivo model of early postnatal cerebellar development. These findings establish VAV1 as a critical epigenetically regulated oncogene with a key role in MB SHH maintenance, and highlight its potential as a validated therapeutic target and prognostic biomarker for the improved therapy of medulloblastoma.
INTRODUCTION
Medulloblastoma, the most common malignant brain tumor of childhood, comprises four consensus molecular subtypes (Wnt/ Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Group 4) characterized by distinct clinical, molecular and pathological features, and by different postulated cells of origin. [1] [2] [3] [4] These advances are rapidly informing targeted therapeutic strategies and the design of individualized clinical trials aimed at increased cure rates and reduced long-term treatment side-effects. 5 Targeted therapies for SHH subgroup medulloblastomas (MB SHH ;~25% of patients) are currently most advanced. MB SHH (~70% 5-year survival) peak in infancy, but also occur throughout childhood and into adulthood. 2 Tumors are characterized by SHH signaling activation via mechanisms including pathway mutations (PTCH1 (~45% of MB SHH ), SUFU (~8%) and SMO (~14%)) and gene amplifications (GLI2 (~8%), MYCN (~13%)). 6 Early clinical trials of SHH pathway inhibitors (targeting SMO) show promise, 7, 8 but significant challenges are predicted in their application, with reported developmental toxicities, 9 acquired drug resistance 10 and intrinsic insensitivity in tumors with pathway activation downstream of SMO (for example, SUFU mutation, GLI2 and MYCN amplification). 6 Thus, there is a clear need to identify additional targetable genes and pathways in MB SHH , to support additional or alternative targeted therapeutic strategies.
The identification of therapeutically exploitable 'driver' events from the many aberrations identified in contemporary genome-wide genetic and epigenetic investigations represents a major challenge. Recent genome-wide mutational screens in MB SHH have revealed notable genetic diversity, however, the most frequent novel coding mutations characterize small patient groups (for example, MLL2 (~16% of MB SHH ) and DDX3X (~26%)) and most mutations are found singly in individual tumors. 6, 11 Significantly, a prominent role for epigenetic alterations is also emerging. 6, [12] [13] [14] [15] Our recent DNA methylation profiling study of 230 medulloblastomas showed MB SHH harbor specific DNA methylation events, which characterize significant proportions of tumors and identify candidate disease driver genes. 15 However, their functional relevance and contribution to tumor development is unknown.
Genetically engineered mouse models, which give rise to medulloblastoma with constitutive SHH pathway activation, support granule neuron precursors (GNPs) of the developing cerebellum as their cells of origin 4, [16] [17] [18] [19] and provide opportunities to systematically interrogate epigenetic events in the mouse medulloblastoma genome. It may be reasoned that any conservation of aberrant DNA methylation events between MB SHH and SHH-driven mouse medulloblastomas could identify events important in tumorigenesis and provide faithful model systems for their functional investigation.
Here we report a cross-species investigation of DNA methylation events in medulloblastomas from 230 human patients (216 with subgroup assigned (50 MB SHH , 28 WNT, 44 Group 3 and 94 Group 4)) and 4 independent SHH mouse models. Using this approach, we identify regional hypo-methylation of VAV1, leading to its elevated expression, as a conserved and widespread epigenetic event in both species, affecting the majority of MB SHH tumors. We further show (i) VAV1 status predicts poor treatment outcome within the MB SHH subgroup and (ii) VAV1 has a critical functional role in medulloblastoma maintenance, highlighting its clear potential as a biomarker and validated drug target in MB SHH . Finally, we provide evidence that Vav1 is expressed in early cerebellar GNPs, where its activity regulates their development. The roles characterized for VAV1 in MB SHH , and in cerebellar Gene Cross-species conservation of methylation status Human 
Hypo-methylated genes in human
Hyper-methylated genes in human . Heatmap shows methylation scores (green (unmethylated) to red (fully methylated)). All CpG sites selected showed a statistically significant difference in average methylation status between groups (mean β difference 40.34 and adjusted Po0.05 following correction for multiple testing). (b, c) The DNA methylation status (methylation score) of orthologous regions in the mouse and human genomes (mean, based on all CpG sites) was calculated for each gene of interest by bisulfite sequencing of 12 spontaneous medulloblastomas arising from four independent Shh-associated mouse models (genotypes indicated) and 11 strain-matched normal cerebella, in comparison with six MB SHH human tumors and six human cerebella. (b) Heatmap shows methylation scores, from green (unmethylated) to red (fully methylated) for individual mouse tumors and cerebella. 'P' indicates significance following Mann-Whitney tests. The difference between the average DNA methylation score for mouse cerebella, and the average methylation score for mouse tumor samples, is shown. (c) Heatmap comparing average methylation scores in all analyzed tumors (T) and cerebella (C) from mice and humans. Conservation of overall methylation status between species (average methylation score difference ⩽ 0.2) is indicated (Y, yes; N, no).
development, demonstrate the potential of comparative tumor epigenomics using genetically engineered mice to identify, prioritize and functionally analyze critical molecular events in human tumorigenesis.
RESULTS

Human MB SHH tumors harbor distinct and characteristic DNA methylation events
We first sought to identify DNA methylation events, which may contribute to human MB SHH . We have previously shown the four major medulloblastoma molecular disease subgroups-WNT, SHH, Group 3 and Group 4-may be distinguished based on their DNA methylation patterns (Supplementary Figure S1A ). 15 Comparison of tumor DNA methylation patterns of subgrouped medulloblastomas (n = 216) with the normal cerebellum (n = 21) showed normal cerebella form a distinct group, which is most closely related to MB SHH (Supplementary Figure S1B ). Statistical analysis identified 15 genes (associated with 18 CpG sites) whose methylation status significantly distinguished MB SHH from other medulloblastomas, and from the normal cerebellum ( Figure 1a ). Both hypo-(n = 6) and hyper-methylation (n = 9) events were observed. In addition, the methylation status of RASSF1A and COL1A2 CpG sites, two of the most frequent hypermethylation events reported in medulloblastoma, 12, 20 was assessed and showed expected frequent and tumor-specific methylation, which affected all tumor subgroups ( Figure 1a ). In summary, these investigations show MB SHH harbor distinct DNA methylation patterns and identify a series of gene-specific DNA methylation events for further analysis.
Identification of conserved DNA methylation events in mouse models of SHH-driven medulloblastoma We next assessed the DNA methylation status of regions orthologous to those encompassing the CpG sites identified in human MB SHH tumors, in medulloblastomas from four independent SHH-associated mouse models, alongside strain-matched normal cerebella of different developmental stages. Eight orthologous regions surrounding CpG sites, which showed MB SHH -specific methylation, alongside regions surrounding RASSF1A and COL1A2, were selected for analysis by direct bisulfite sequencing (Figure 1 , Supplementary Table S1 and Supplementary Figures S2A and B ). The overall cerebellar methylation status was conserved in the majority of regions assessed (7/10; Figure 1c ); cerebella from different mouse strains, including immature and mature mice, showed equivalent patterns ( Figure 1b ). Consistent methylation profiles were also observed across tumors from the different SHH-associated mouse models ( Figure 1b ).
Most strikingly, VAV1 showed widespread tumor-specific patterns of hypo-methylation across the regions examined which were of equivalent extent, magnitude and frequency in human MB SHH and SHH mouse tumor models, compared with cerebellar controls. In all mouse tumors, the majority of CpG sites across the Vav1 region were hypo-methylated (Figures 1b and c; Supplementary Figure S2C ), while in humans, VAV1 hypomethylation encompassed all assessed CpG sites (Supplementary Figures S2B and S3A-C). Tal1, Dsc2, Spdef and Rassf1a also showed statistically significant methylation differences, but these represented methylation changes in individual samples or CpG sites and were not comparable to differences seen between human MB SHH tumors and cerebella (Figures 1b and c) . These findings identify regional VAV1 hypo-methylation as a frequent evolutionarily conserved epigenetic event in human MB SHH , for further analysis.
VAV1 hypo-methylation characterizes the majority of MB SHH and is associated with a poor outcome VAV1 hypo-methylation was a frequent region-wide event in human MB SHH (70% (36/50)), affecting only occasional tumors (2% (4/166)) within the other molecular subgroups ( Figure S3C ). In whole-cohort analysis (n = 230), VAV1 hypo-methylation was significantly correlated with desmoplastic nodular pathology (P = 2.3 × 10 − 11 , Fisher's exact test), infant patients (o 3 years at diagnosis; P = 0.003)) and MYCN gene amplification (P = 0.02) ( Figure 2c ), consistent with the established associations of these features with MB SHH in this cohort. 15 Within the MB SHH subgroup, VAV1 hypo-methylation was observed across tumors of all key clinical, pathological and molecular demographics, and did not associate with any particular medulloblastoma disease feature; it is, however, notable that all MYCN amplifications occurred in VAV1 hypo-methylated tumors ( Figure 2c ). Associations were assessed using the CpG site recognized by the VAV1_e9 probe, which lies within the region conserved between humans and mice. Notably, VAV1 hypomethylation was associated with a poor outcome among MB SHH tumors (Figure 2d ), in an analysis of 36 patients aged ⩾ 3 years at diagnosis, who received standard upfront radiotherapy and chemotherapy and were derived predominantly from the PNET3 clinical trial. 15, 21 The rarity of VAV1 hypo-methylation in non-MB SHH precluded the analysis of any relationships to survival in these subgroups. Thus, VAV1 hypo-methylation occurs frequently within the MB SHH subgroup and is associated with specific disease features and poor outcomes.
VAV1 hypo-methylation is associated with elevated expression in human and mouse SHH medulloblastomas VAV1 showed a direct methylation-dependent relationship between methylation status and expression in human medulloblastoma cell lines treated with the DNA methyltransferase inhibitor, 5'-Aza-2'-deoxycytidine (5-azaCdR) (Figures 3a and b ). All VAV1-methylated cell lines (D283Med, MEB-Med8a and D425Med) had low VAV1 expression, which was upregulated following 5-azaCdR demethylation. In contrast, VAV1 expression was higher in hypo-methylated cells (DAOY) and was unaffected Figure 2 . VAV1 hypo-methylation in MB SHH : incidence, regional distribution and association with clinical, pathological and molecular disease features. (a) VAV1 methylation levels in our cohort of 216 primary medulloblastomas with subgroup classification. Box plots show methylation levels (β-value, probe E9) in the MB SHH subgroup (n = 50) compared with non-MB SHH tumors (n = 166) and normal cerebella (CB; n = 21). The cerebellar methylation distribution (mean-3 s.d.; cutoff marked) was used to distinguish hypo-methylated tumors (β o0.53) for subsequent assessment of clinical, pathological and molecular associations. 'P'-value, Kruskal-Wallis test. Non-MB SHH tumors are shown colored by subgroup (Group 3, yellow; WNT, blue; Group 4, green). (b) Methylation levels at adjacent CpG sites to probe E9, following analysis by bisulfite sequencing in representative MB SHH , non-MB SHH tumors and normal cerebella samples showing region-wide hypo-methylation of CpG sites in the majority of MB SHH tumors. CpG sites are labeled by their position relative to the translational start site of VAV1. Black circles, ⩾ 80% methylation; three-quarter black circles, ⩾ 60%; half black circles, ⩾ 40%; quarter black circles, ⩾ 20% methylation; white circles, o20% methylation. (c) Clinical, pathological and molecular features of VAV1-methylated and hypo-methylated tumors. 'P'-values, χ 2 or Fisher's exact test, as appropriate. (d) Kaplan-Meier survival curves show event-free survival (EFS) for VAV1 hypo-methylated and methylated tumors (β-value, probe E9) in a subcohort of 36 primary MB SHH medulloblastomas comprising patients with available survival information, aged ⩾ 3 and o16 years at diagnosis, treated with standard upfront radiotherapy and chemotherapy. 15 'P'-value, log-rank test.
by 5-azaCdR. Consistent with this, Vav1 expression was significantly increased in mouse tumors (all hypo-methylated) compared with normal adult cerebella (all methylated) ( Figure 3c ; Supplementary Figure S2C ), and in VAV1 hypo-methylated human tumors compared with VAV1-methylated tumors or the normal human cerebellum (all methylated) ( Figure 3d ). Finally, VAV1 expression was highest in MB SHH tumors (associated with VAV1 hypo-methylation) compared with the other medulloblastoma molecular subgroups ( Figure 3e ; data from published data set 22 Hypomethylated and hypo-methylated (n = 12) human tumors and methylated human normal cerebella (CB; n = 5). VAV1 methylation status was determined as described in Figure 2 . (e) VAV1 mRNA expression in a cohort of 255 primary human medulloblastomas previously described by Northcott et al. 22 containing no WNT subgroup tumors. (d, e) Molecular subgroup status is shown for human medulloblastomas (MB SHH , red; WNT, blue; Group 3, yellow; Group 4, green; not classified, grey), and 'P'-values (c, t-test; d, e, analysis of variance (ANOVA)) are indicated.
expression are consistent with the hypo-methylation-dependent elevation of VAV1 expression in human and mouse SHH subgroup medulloblastomas.
VAV1 expression is pro-proliferative in human medulloblastoma cells
To investigate the functional consequences of VAV1 hypomethylation and expression in human medulloblastoma, we modeled the effect of silencing VAV1 overexpression in hypo-methylated human medulloblastoma cells. VAV1 silencing using small interfering RNA (siRNA; 60-80% knockdown, day 3; Figures 4a and b) significantly decreased proliferation ( Figure 4c ) and altered cell cycle distribution; a pronounced G 2 arrest and increased G 0 /sub-G 1 fraction occurred following VAV1 knockdown ( Figure 4d ). These data support a pro-proliferative role for the elevated VAV1 expression observed in VAV1 hypo-methylated human medulloblastoma cells. Figure S2C ) and infected them with retroviruses carrying green fluorescent protein (GFP) alone, wildtype Vav1/GFP or a dominant-negative form of Vav1 (Vav1DN/ GFP), 23, 24 an isolated amino terminal fragment (residues 1-186), which acts in trans to inhibit the guanine nucleotide exchange factor (GEF) function of native Vav1. Cells from each infected pool were transplanted in the flanks of recipient nude mice and tumor formation assessed.
Approximately 2 months post-implantation, tumors appeared on the flanks of all mice transplanted with tumor cells marked with GFP-only or with Vav1/GFP viruses. These tumors harbored similar weights (Figure 5c ). In contrast, tumors that developed after the transplant of tumor cells infected with Vav1DN-carrying viruses were smaller than those derived from GFP-only-infected cells and only six out of nine transplants induced secondary tumors (Figures 5a-c) . Thus, enforced expression of a Vav1 dominant-negative mutant inhibits tumor maintenance in our model. Ectopic overexpression of wild-type Vav1 did not impact, suggesting interference with the endogenous Vav1 expression associated with its hypo-methylation is important for the inhibition of tumor growth.
To examine the contribution of retrovirally infected cells to tumor development, we analyzed by fluorescence-activated cell sorting (FACS) the percentage of infected GFP-positive tumor cells before transplant and in each secondary tumor. On average, we found a~40% reduction of Vav1DN-infected GFP + cells in secondary tumors compared with the initially infected pool (Figure 5d ). In contrast, when tumor cells were infected with GFP-only retroviruses, the percentage of GFP-positive cells increased by~20% in the secondary tumors (Figure 5d ). Consistent with the tumor weight, enforced wild-type Vav1 expression did not affect the percentage of GFP + cells in the secondary flank tumors (Figure 5d ).
In contrast, enforced wild-type Vav1 expression did not appear to contribute significantly to medulloblastoma initiation in the Ptch1 +/ − Cdkn2c −/− model. Cerebellar GNPs, the cell type of origin of MB SHH , were enriched from the cerebella of postnatal (P) day 7, Ptch1 +/ − Cdkn2c −/− pups, then infected with retroviruses carrying GFP alone or co-expressing wild-type Vav1. Mycn-carrying retroviruses were used as a positive control. 25 Average infection efficiencies were comparable (30.86% for GFP, 35.34% for Vav1/ GFP and 40.28% for Mycn/GFP). Tumors failed to develop 46 months after stereotactic transplantation of GNPs, infected with GFP-only containing virus (n = 7) or co-expressing wild-type Vav1 (n = 8), into the cerebral cortex. GNPs infected with a Mycn containing retrovirus induced medulloblastomas within 2 months as previously shown (n = 7/7) 25 (Figure 5e ). In summary, dominantnegative Vav1 suppressed medulloblastoma maintenance in our Ptch1 +/ − Cdkn2c −/− mouse model. Vav1 activity regulates GNP germinal zone exit and migration initiation in normal cerebellar development We next examined whether Vav1 activity had any effect on the development of GNPs and postmitotic cerebellar granule neurons (CGNs). GNPs are located near the cerebellar surface in a germinal zone (GZ) called the external germinal layer (EGL), whereas after cell cycle exit and neuronal differentiation, CGNs exit their GZ by migrating away from the EGL to cross the molecular layer and eventually reside within the internal granule layer (IGL). 26 GNP or CGN position with the developing cerebellar cortex thus represent an excellent model to examine neuronal progenitor maturation, as cells of the CGN lineage occupy stereotyped positions in the developing cerebellar cortex dependent upon their differentiation status. 26 We first found Vav1 was expressed at elevated levels in developing (P7) GNPs compared with cerebella from wild-type mice (Figure 6a ). Then, we used electroporation of early postnatal mouse cerebellum followed by ex vivo culture of organotypic cerebellar slices as an assay to examine GNP GZ exit and migration initiation. 27 Expression constructs for Vav1DN and the fluorescent nuclear reporter H2B-mCherry were co-electroporated into the cerebellar cortices of P7 mice and cerebellar slices were cultured ex vivo. Although control GNPs remained within the EGL after 24 h, cells expressing elevated Vav1DN entered the molecular layer and IGL (Figures 6b and d ), suggesting that inhibition of Vav1 activity is sufficient to induce precocious GZ exit.
Given that Vav1 inhibition appeared to regulate GNP GZ exit and migration initiation, we next evaluated whether Vav1 activity could regulate GNP's GZ exit using a gain-of-function approach. Expression vectors for a constitutively active Vav1 lacking the autoinhibitory amino terminal domain (Vav1CA) 28 were electroporated into P7 EGL. After 2 days of ex vivo culture, control CGNs initiated migration correctly and had entered the molecular layer and IGL, whereas Vav1CA-expressing CGNs remained within the EGL (Figures 6c and e ), suggesting that activation of Vav1 activity blocks GZ exit. Finally, we examined the morphology of Vav1DN and Vav1CA-overexpressing cells via time-lapse microscopy of in vitro CGN cultures. Although control neurons and Vav1DNexpressing neurons elaborated the long neurites of mature CGNs, Vav1CA expressing retained the short processes, which are the characteristic of immature CGNs (See Supplementary Movies 1-3) .
Together, these data show Vav1 activity blocks GNP exit from the developing cerebellar GZ and indicate a role in normal cerebellar development.
DISCUSSION
Our investigations of DNA methylation events in human MB SHH and four independent SHH mouse medulloblastoma models have identified VAV1 hypo-methylation as a conserved and defining MB SHH event, which affects around 70% of human tumors, more common than any mutated gene (PTCH1 (~45%) and TERT (~30%) are most frequent), 6, 29, 30 and which describes MB SHH of all key clinical, pathological and molecular demographics. Its complete regional demethylation (Supplementary Figure S3) , coupled with an absence of significant copy number alterations or mutations in large cohorts (data from Northcott et al. 11, 22 ) indicates hypomethylation is its major mechanism of alteration. VAV1 methylation status is intimately related to its expression; VAV1 expression is controlled by methylation in human cell lines and its hypomethylation, in both mouse and human tumors, is significantly associated with increased expression. Consistent with this, the region of uniform hypo-methylation, we have characterized overlaps with the minimal region shown in mutagenesis studies to be sufficient to drive VAV1 expression. 31 Modeling VAV1 epigenetic silencing in mouse and human tumor models validated a role for VAV1 expression in SHHassociated tumor growth and maintenance. Introduction of dominant-negative Vav1 into tumor cells from established hypomethylated Ptch1 +/ − Cdkn2c −/− mouse tumors significantly reduced tumor re-establishment and growth. In contrast, enforced expression of wild-type Vav1 did not further increase tumorigenic potential, indicating endogenous Vav1 levels in hypo-methylated cells are sufficient to promote tumorigenesis. Further, the impact of VAV1 silencing on proliferation and cell cycle arrest in VAV1 hypo-methylated human cells is consistent with VAV1-dependent effects in other cancer cell types, 24, 32 whereas the identification of Vav1 mutation as a SHH-cooperating event in a murine insertional mutagenesis screen 33 provides further genetic evidence to substantiate its role in MB SHH . Any role for VAV1 in tumor initiation is less clear; enforced Vav1 expression in engrafted Ptch1 +/ − Cdkn2c −/− GNPs did not cause tumor development, in contrast to Mycn controls. 25 However, given Ptch1's established role in initiation, 34 these results do not preclude Vav1 involvement. Future strategies to examine any interaction between Ptch1 and Vav1 in spontaneous SHH tumor formation, which account for endogenous Vav1 expression 35 should prove informative.
The role of VAV1 in the majority of MB SHH tumors, together with the inhibition of tumor growth following its silencing, identify and validate VAV1 and its dependent pathways as important potential therapeutic targets. In particular, its homogeneous mechanism of activation and SHH independence highlight potential applications for alternative or second-line/combination therapies with SHH pathway inhibitors. Consistent with its pro-tumorigenic role, VAV1 hypo-methylation was associated with a poor outcome in clinical trial-derived MB SHH patients, 15, 21 supporting its utility as both a prognostic and predictive biomarker for use in stratified therapies. Multivariate survival analysis, validation in alternative cohorts and investigations in all disease demographic groups are now essential to confirm reproducibility of these initial findings before any clinical application.
Vav1 is expressed in GNPs (the proposed cells of origin for MB SHH ) 36 during early cerebellar development. Our data show its activity blocks GNP exit from the developing cerebellar GZ, suggesting a mechanism by which disruption of these processes by Vav1 hypo-methylation and expression may contribute to medulloblastoma tumorigenesis. These findings further emphasize the intimate links between cerebellar development and medulloblastoma, and evidence that temporally/spatially restricted pathways in normal cerebellar development become constitutively activated during tumorigenesis. 36 Coupled with the established roles of SHH pathway activation in GNP proliferation 34 and MB SHH , our data also suggest common functions for Vav1 and SHH in both processes, and provide a basis for the investigation of any functional interaction. Interestingly, Vav3 has roles in the migration of GNPs from the EGL to the IGL, and in the survival of GCNs in the IGL, 37 implicating the involvement of multiple Vav family members in cerebellar development. Consideration of developmental toxicities will thus be essential in developing targeted therapies against VAV1, however, that Vav1 −/− mice are viable and healthy apart from impaired T-cell development 38 is encouraging. How may VAV1 exert its function? VAV1 expression is normally confined to the hematopoietic system, where its bestcharacterized function is as a GDP/GTP nucleotide exchange factor for the Rho/Rac family of GTPases. However, roles in multiple diverse processes including activation of the c-Jun N-terminal kinase, extracellular signal-regulated kinase, Ras, nuclear factor-kB and nuclear factor of activated T-cells (NFAT) pathways, cytoskeleton organization, migration and TP53mediated apoptosis have also been described. 32, 39, 40 Direct small molecule VAV1 inhibitors are not widely reported, however, strategies against many of its candidate downstream pathways are in development. 41 A detailed exploration of the pathways impacted by VAV1 in MB SHH and normal cerebellar development will therefore now be essential to understand their mechanistic basis and to enable therapeutic targeting.
Finally, available evidence suggests an emerging widespread relevance for VAV1 in tumor development. In addition to its expression in hematopoiesis and hematological malignancies, 42 VAV1 expression has been reported in solid tumors including neuroblastomas 32 and pancreatic ductal adenocarcinomas, where expression was associated with a poor survival outcome, and with demethylation of the VAV1 promoter in tumor cell lines. 24 In preliminary investigations of other pediatric brain tumor types, VAV1 hypo-methylation at the CpG residues involved in MB SHH is also a feature of a proportion of posterior fossa ependymomas, high-grade gliomas and central nervous system primitive neuroectodermal tumors (CNS-PNETs), as well as occasional non-MB SHH medulloblastomas (Supplementary Figure S4 ; Figure 2 ), suggesting potential roles in their development for further investigation.
MATERIALS AND METHODS
Patient samples, DNA methylation profiling and subgroup status DNA methylation profiling and consensus clustering of molecular subgroups was performed as previously described 15 on 230 primary medulloblastomas (of which 216 were confidently assigned to a subgroup), alongside 21 normal non-neoplastic cerebella (representing fetal, infant and adult samples), 43 using the Illumina GoldenGate Cancer Panel I microarray. 44 The DNA methylation status of 1505 CpG sites (807 genes) was represented as a β-score from zero (unmethylated) to one (methylated). Subgroup status was additionally assessed using mRNA signature, 45 immunohistochemistry 46 and mutational (CTNNB1) 45 biomarker assays.
5-AzaCdR treatment of human cell lines
Four human medulloblastoma cell lines (D283Med, MEB-Med8a, D425Med and DAOY) were grown in the presence or absence of the demethylating agent 5-azaCdR as previously described. 12 Cell lines were validated by confirmation of published karyotypes. 47 Mouse tumor and tissue samples Nucleic acid extraction DNA and RNA were extracted from frozen tumors, tissues and cell lines using Trizol (Invitrogen, Carlsbad, CA, USA), and DNA from formalin-fixed, paraffin-embedded samples using a Qiagen DNeasy kit (Qiagen Ltd, Valencia, CA, USA), according to the manufacturer's instructions.
Identification of differentially methylated CpG sites
CpG sites showing significant differences between the SHH and other medulloblastoma subgroups (combined) were identified (Mann-Whitney U-test, retaining probes significant (Po0.05) after Benjamini-Hochberg false discovery rate correction). All CpG sites identified showed an absolute change in average (mean) β ⩾ 0.34 between these groups. Differences in CpG methylation between the SHH subgroup and normal cerebella were assessed equivalently.
Analysis of DNA methylation status by bisulfite sequencing
Bisulfite DNA treatment was carried out using the Epitect bisulfite kit (Qiagen Ltd), and PCR using standard reaction conditions ( Supplementary  Table S2 ). Purified products were directly sequenced with a CEQ DTCS kit (Beckman Coulter, High Wycombe, UK) and analyzed on a CEQ 2000XL DNA analysis system (Beckman Coulter). The methylation status at each CpG residue was determined by assessment of relative peak intensities, as previously described. 12 The DNA methylation status (methylation score) of orthologous regions in the mouse and human genomes (mean, based on all sequenced CpG sites) was subsequently calculated for each region of interest.
cDNA synthesis and quantitative reverse transcriptase-PCR Complementary DNA (cDNA) was synthesized from total RNA using a Biorad iScript cDNA synthesis kit (Bio-Rad, Irvine, CA, USA) according to the manufacturer's instructions. Measurements of VAV1 transcript levels in mouse and human samples were determined using SYBR Green on the ABI PRISM 7900HT Detection System (Applied Biosystems, Foster City, CA, USA), using the comparative Ct relative quantification method ( Supplementary Table S2 ).
RNA interference
Cells were seeded in 6-or 96-well plates and allowed to adhere for 24 h, then transfected with 40 nM siRNA duplexes to VAV1 (sense strands: duplex 1: 5′-CGUCGAGGUCAAGCACAUUdTdT-3′; 48 duplex 2: 5′-GCCAUCAGCA UUAAAUAUAdTdT-3′, duplex 3: 5′-UCAAAUACAAGGAGAGGUUdTdT-3′ (DharmaconGE, Lafayette, CO, USA) or negative control siRNA duplexes (sense 5′-UUCUCCGAACGUGUCACGUdTdT-3′ (Qiagen Ltd)) using Lipofectamine RNAiMAX (Invitrogen), following the manufacturer's instructions.
Growth assays
Cells were seeded at 1 × 10 3 in 96-well plates and allowed to adhere for 24 h. The number of viable cells at day 0 (before siRNA addition) and days 1-5 (after addition) was quantified using an XTT cell proliferation assay kit (Roche, Hertfordshire, UK) according to the manufacturer's instructions. Experiments were performed in quadruplicate.
Flow cytometry
Adherent cells were harvested with trypsin 36 and 48 h after siRNA transfection, fixed in ice-cold 70% ethanol/30% phosphate-buffered saline solution, then resuspended in 40 mg/ml propidium iodide/0.1 mg/ml RNAse A (Sigma-Aldrich, Gillingham, UK) at 37°C for 30 min, and assessed using a FACScan (Becton Dickinson, Oxford, UK) and Modfit software (Verity Software, Topsham, ME, USA). Experiments were performed in quadruplicate.
Retrovirus production
Plasmids used for retrovirus production were generated using the mouse stem cell virus (MSCV) LTR backbone expressing the GFP downstream of the internal ribosomal entry site (IRES) pMSCV-IRES-GFP. The full-length Vav1 cDNA (amino acids 1-845 (pMSCV-Vav1-IRES-GFP)) and the N-terminal region (amino acids 1-186 (pMSCV-Vav1DN-IRES-GFP)) were inserted downstream of the MSCV LTR in the pMSCV-IRES-GFP plasmid. The pMSCV-Mycn-IRES-GFP construct and generation of retroviral stocks were previously described. 25 Mouse cerebellar and tumor cell purification, virus infection and orthotopic transplantations GNP-enriched mouse cerebellar and medulloblastoma cells were purified by percoll gradient. 25, 49 Purified cells were plated on Matrigel-coated dishes and infected with retroviruses (GFP alone, Vav1-IRES-GFP, Vav1DN-IRES-GFP and Mycn-IRES-GFP). Two days after infection, cells were harvested, resuspended in Matrigel (BD Biosciences, San Jose, CA, USA) and transplanted into CD-1 nu/nu mice (2.0 × 10 6 cells per injection) as previously described. 25 GNPs infected with GFP alone, Mycn-IRES-GFP or Vav1-IRES-GFP retroviruses were transplanted into the cortices of recipient mice. Virally infected tumor cells were transplanted in the flank of naive recipient animals. Cortically transplanted animals were killed, when neurological symptoms were confirmed. Flank injections of virally marked tumor cells were performed on both sides of each mouse; in the left side, 2.0 × 10 6 tumor cells infected with GFP and on the other side, the same number of tumor cells infected with either Vav1/GFP or Vav1DN/GFP retroviruses. In parallel, a subset of infected cells was analyzed by FACS to calculate the efficiency of infection reflected by the percentage of GFP + cells. Transplanted mouse recipients were monitored daily; tumors were harvested and weighed, and tumor cells purified by Percoll gradient and analyzed by FACS for GFP expression as previously described. 3 
Protein lysate preparation and immunoblotting
Whole-cell extracts were prepared from human cell lines, wild-type 1-month-old whole cerebella, Percoll-purified GNPs from P7 cerebella and mouse Ptch +/ − medulloblastomas. In all, 25-35 mg protein per sample was separated by gel electrophoresis and immunoblotted with defined antibodies as previously described. 12 Primary antibodies were VAV1 (C14; Santa Cruz, Santa Cruz, CA, USA), Actin (Sigma-Aldrich) and HSC70 (K19; Santa Cruz). Appropriate secondary antibodies with horseradish peroxidise conjugates (Dakocymation Ltd, Glostrup, Denmark) were bound to the primary antibodies, followed by incubation with enhanced chemiluminescence (ECL or Dura) substrate (Pierce, Rockford, IL, USA), visualization by autoradiography, and densitometry using a Fuji-Las camera (Fujifilm Corporation, Tokyo, Japan) and the AIDA image analyzer program (Raytek, Sheffield, UK).
Ex vivo cerebellar electroporation, organotypic slice culture and imaging Plasmids for ex vivo cerebellar slice experiments were generated using the pCIG2 vector, which contains a CAG promoter for high-level expression in CGNs and GNPs. The dominant-negative form of Vav1 (Vav1DN), the constitutively active form of Vav1 (Vav1CA) or H2B-mCherry cDNAs were inserted downstream of the CAG promoter in the pCIG2 expression vector.
Ex vivo cerebellar electroporation and organotypic slice culture was performed on P7 mouse cerebella as described previously. 27 Migration distance measurements of fixed slices were performed by marking the center of individual cell nuclei marked by mCherry-H2B using the pen function of SlideBook (Intelligent Imaging Innovations, Denver, CO, USA), exporting the cellular coordinates and calculating the distance between the center of each cell and the cerebellar surface using a custom written algorithm in Igor Pro (Wavemetrics Inc., Lake Oswego, OR, USA). All measurements were analyzed statistically using Microsoft Excel and graphed using Kaleidagraph v4.03 (Synergy Software Systems, Reading, PA, USA).
Statistical analysis
All array-based bioinformatic and statistical analyses were performed using R (v2.15.0) 50 and the stated statistical test. Survival analyses were performed using event-free survival times. 15 
